Acute Respiratory Distress Syndrome Market | ARDS Market

1. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET INSIGHTS, EPIDEMIOLOGY&MARKET FORECAST-2027

2. ACUTE RESPIRATORY DISTRESS SYNDROME • Acute Respiratory Distress Syndrome (ARDS) is a life- threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs. • ARDS is also classified on the basis of severity of disease as Mild ARDS, Moderate ARDS and Severe ARDS by Berlin definition. It is generally characterized into three stages such as exudative stage, fibro proliferative (or proliferative) stage, resolution and recovery stage. • DelveInsight © 2018 | All rights reserved

3. EPIDEMIOLOGY INSIGHTS Cross-sectional studies demonstrate that patients with ARDS represent approximately 5% of hospitalized, mechanically ventilated patients. ARDS occurrence varies consistently, ranging from 10.6 per 100,000 person-years in Finland, to 17.9 per 100,000 person-years in Scandinavia, to 25.5 per 100,000 person-years in Spain. 1 3 2 4 DelveInsightestimates ARDS incidence has varied from 1.3 to 22 per 100,000 person years. Mild ARDS represents only 25% of patients with ARDS, approximately 75% of patients are reported with moderate or severe ARDS. • DelveInsight © 2018 | All rights reserved

4. 4 MARKET INSIGHTS • Extensive research and development activities of pharmaceutical companies are being carried out for developing the therapies for ARDS along with the emerging therapies in the pipeline • Expected launch of BioMark Pharmaceuticals’ BIO-11006, Techpool, Bio-Pharma‘s Ulinastatin and other therapies shall impact the market size of ARDS ARDS • Owing to the launch of upcoming therapies, the market size shall increase significantly during forecast period (2018-2027) • There are many potential pipeline drugs expected to enter ARDS market by XXXX and subsequent years. • Market Size of ARDS in the 7MM was found to be XXX in 2016 • DelveInsight © 2018 | All rights reserved

5. 5 KEY PLAYERS 01 BioMarck Pharmaceuticals 02 Techpool Bio-Pharma 03 Faron Pharmaceuticals • DelveInsight © 2018 | All rights reserved

6. COMPLETE INFORMATION For complete information please click below Or Write to us at info@delveinsight.com CLICK HERE • DelveInsight © 2018 | All rights reserved

7. 7 ABOUT DELVEINSIGHT DelveInsight, market research and consulting firm, provides end to end comprehensive solutions to the Life Science Industry. We help our customers in best decision making through our expertise in research & analysis and comes out with unmatched data & forecasts Vision “Insight across the value chain” to help organizations make important business decisions through the use and analysis of actionable market intelligence • Mission • To be the most trusted marketing research firm & business consulting firm worldwide. • To be a renowned and premier data driven solution providers among Pharma & Biotech companies. 01 02 03 • DelveInsight © 2018 | All rights reserved

8. Comprehensive solution for strategic business decisions SERVICE OFFERINGS AT DELVEINSIGHT • Market Size • Market Dynamics • Market Assessment MarketIntelligence Consulting • Drug Sales Forecast • Indication Forecast • Late Stage Pipeline Analysis Forecasting • Asset Prioritization • Brand Optimization • Portfolio Expansion • Competitive landscape • Clinical Trials • Therapeutic Assessment • Opportunity Assessment for • Licensing • Market Access • Partnership • Primary Analytics • News-Letters • Conference Tracking • Clinical Trials Tracking • Access over 3000+ Reports • API • Market & Pipeline • Indication & Epidemiology Competitive Analysis Pipeline OA Report Store SociAlytics • Trends Analysis • Physicians & Patients Perception • KOLs • DelveInsight © 2018 | All rights reserved

9. Add a Slide Title - 5 Contact Us: info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight/ twitter/delveInsight LinkedIn/delveInsight